原料辞典検索/cetearyl-glucoside/CETEARYL GLUCOSIDE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

CETEARYL GLUCOSIDE

標準 INCI 準拠: CETEARYL GLUCOSIDE
乳化剤洗浄剤
[EU CosIng Official Definition] D-Glucopyranose, C16-18 alkyl glycosides
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における CETEARYL GLUCOSIDE のグローバル配合基準と処方特性とは?

CETEARYL GLUCOSIDE(CAS番号: 246159-33-1)は、化粧品処方において主に乳化剤, 洗浄剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 1–5%(適正安定域 pH 3–10)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for CETEARYL GLUCOSIDE
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)CETEARYL GLUCOSIDE (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)CETEARYL GLUCOSIDE
④ 米国一般化粧品 (US PCPC / MoCRA INCI)CETEARYL GLUCOSIDE
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)鲸蜡硬脂基葡糖苷
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)CETEARYL GLUCOSIDE (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for CETEARYL GLUCOSIDE
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #3636
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for CETEARYL GLUCOSIDE
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 5%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03508 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 3%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03508 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=118
Min 1% · Q1 1.5% · Median 2.5% · Q3 3.5% · Max 5%
Emulsion / Cream — COSMOS-approved alkylpolyglucoside lamellar emulsifier
Verified Source: SEPPIC MONTANOV 68 TDS & Formulation Library (cir_safety) · SEPPIC 88 · Evonik 20 · Croda 10
Typical Median: 2.5%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for CETEARYL GLUCOSIDE
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 B — 乳液・エマルジョン・クリーム1% · 1.5% · 2.5% · 3.5% · 5%COSMOS-approved alkylpolyglucoside lamellar emulsifierSEPPIC MONTANOV 68 TDS & Formulation Library
Cutaneous Permeation Science (500 Dalton Rule)MW: 546.7 Da · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesBio-Spicule Micro-Needle (180–250 µm)Physical Micro-Channel ConduitDermal Delivery (~14.2x Flux)
Molecular Weight & LogP Permeation Diagnosis
Macromolecule (546.7 Da > 500 Da) — Transdermal Booster Required

Co-formulating with 0.1–0.5% Hydrolyzed Sponge (Bio-Spicule, 180–250 µm) creates transient micro-channels across the stratum corneum, delivering actives directly into the papillary dermis (PMID: 34112845).

Estimated Target Depth
180–250 µm
Optimal Delivery System
Bio-Spicule + Liposome
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Oil phase with Cetearyl Alcohol (75~80°C)
Optimal Formulation pH Stability Window (0–14)pH 3.0 – 10.0
0245.5791114

Outside pH 3–10, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 85°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 85°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
Lamellar Liquid Crystal Phase (Biomimetic Skin Barrier)
HLB 9.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)Lamellar Bilayer
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ CETEARYL ALCOHOL+ CAPRYLIC/CAPRIC TR…+ SQUALANE+ XANTHAN GUM✕ Requires emulsificat…CETEARYL GLUCOSIDE
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
MONTANOV™ 68TEGO® Care CG 90

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: CETEARYL GLUCOSIDE | CAS No.: 246159-33-1 | EC No.: N/A - Origin: SYNTHETIC | Functions: , - Physicochemical Profile: Formula C28H56O7 | MW 546.7 g/mol | / | Ionic Nature: non-ionic | PubChem CID 6452086 - Official Regional Label Names: US [CETEARYL GLUCOSIDE] · EU [CETEARYL GLUCOSIDE] · CN [鲸蜡硬脂基葡糖苷] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - D-Glucopyranose, C16-18 alkyl glycosides Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3636 (鲸蜡硬脂基葡糖苷)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 5.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 3.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 1.0 ~ 5.0% (Median 2.5%, Ref: SEPPIC MONTANOV 68 TDS & Formulation Library) — COSMOS-approved alkylpolyglucoside lamellar emulsifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Oil Phase (Heat to 75~80°C with Cetearyl Alcohol) - Optimal pH Range: pH 3.0 ~ 10.0 | Max Process Temp: Max 85°C | Electrolyte Tolerance: HIGH - Incompatibility / Caution: Requires emulsification temperature ≥ 75°C to fully melt cetearyl alcohol co-crystals - Synergy Pairings: CETEARYL ALCOHOL, CAPRYLIC/CAPRIC TRIGLYCERIDE, SQUALANE, XANTHAN GUM | Reference Trade Names: MONTANOV™ 68, TEGO® Care CG 90 ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 42289776 (2026, Contact Dermatitis): Alkyl Glucosides in Rinse-Off and Leave-On Cosmetics Available on the Dutch Market - PMID 41707668 (2026, Contact Dermatitis): Allergic Contact Dermatitis to Alkyl Glucosides: Becoming More Relevant in Facial Dermatitis? - PMID 36268749 (2023, Contact Dermatitis): Co-reactivity of glucosides: Retrospective analysis of North American Contact Dermatitis Group Data 2019-2020

関連査読付き学術論文 (NIH PubMed) (12)

Alkyl Glucosides in Rinse-Off and Leave-On Cosmetics Available on the Dutch Market [PMID: 42289776 · 2026]
Yaâkoubi M, Ipenburg NA, Groot AC, Rustemeyer T · Contact Dermatitis (2026)
Allergic Contact Dermatitis to Alkyl Glucosides: Becoming More Relevant in Facial Dermatitis? [PMID: 41707668 · 2026]
Patel K, Brasher TR, Palmer A, Nixon RL · Contact Dermatitis (2026)
Co-reactivity of glucosides: Retrospective analysis of North American Contact Dermatitis Group Data 2019-2020 [PMID: 36268749 · 2023]
Warshaw EM, Xiong M, DeKoven JG, Taylor JS, Belsito DV, Reeder MJ, Adler BL, Pratt MD, Atwater AR, Maibach HI, Silverberg JI, Yu J, Botto N, Fowler JF, Houle MC, Mowad CM, Dunnick CA, DeLeo VA · Contact Dermatitis (2023)
Allergic contact dermatitis in response to cetearyl glucoside from a topical drug [PMID: 34628676 · 2022]
Baudy A, Dereure O, Du-Thanh A, Raison-Peyron N · Contact Dermatitis (2022)
Patch testing with alkyl glucosides: Concomitant reactions are common but not ubiquitous [PMID: 30460735 · 2019]
Bhoyrul B, Solman L, Kirk S, Orton D, Wilkinson M · Contact Dermatitis (2019)

Alkyl glucosides contitute a family of mild surfactants that are increasingly being used in a wide range of cosmetics and household products. Contact allergy to alkyl glucosides may be more frequent than previously suspected, especially in atopic patients. To investigate the frequency of contact allergy to alkyl glucosides, and to identify concomitant reactivity. We retrospectively reviewed all cases of suspected allergic contact dermatitis (ACD) in which patients were patch tested with either a cosmetic series that includes five alkyl glucosides (decyl glucoside, lauryl glucoside, coco glucoside, cetearyl glucoside, and caprylyl/capryl glucoside) or a specific alkyl glucoside series from November 2013 to April 2017 in two UK centres. A total of 5775 patients were patch tested across the two centres. Twenty-nine (1.04%) of the 2796 patients tested with the cosmetic/alkyl glucoside series had a positive patch test reaction to at least one of the alkyl glucosides. Twenty-three (79.3%) patients were sensitized to multiple alkyl glucosides; 21 patients (72.4%) were female. The mean age was 43.5 years. Twelve patients (41.4%) had a background of atopic dermatitis. The prevalence of alkyl glucoside-induced ACD is relatively high, and there are frequent concomitant reactions between different alkyl glucosides. We recommend the inclusion of alkyl glucosides in all cosmetic series.

Allergic contact dermatitis caused by alkyl glucosides [PMID: 24588370 · 2014]
Gijbels D, Timmermans A, Serrano P, Verreycken E, Goossens A · Contact Dermatitis (2014)

Alkyl glucosides were not expected to have a sensitizing potential at the concentrations to be used in finished consumer products; however, several contact allergy cases have been published. To report on the patients suffering from allergic contact dermatitis caused by alkyl glucosides observed in our department. During a 19-year period (1993-2012), 11 842 patients with suspected contact dermatitis were patch tested with the European baseline series and, if relevant, also with other series and individual allergens. For this study, the clinical data and the sensitization sources in the alkyl glucoside-positive patients were analysed. In total, 30 patients (24 women and 6 men) presented with a positive reaction to one or more alkyl glucosides. The causal products were shampoos (in 12), skin-cleansing products (in 12, among which were wipes for intimate hygiene), sunscreen products (in 5), skin-care products (in 4), and a deodorant (in 1). Sixteen patients showed multiple sensitivities (defined as three or more contact allergies), not only to other glucosides, but also to non-related chemicals. Allergic contact dermatitis caused by alkyl glucosides in cosmetics does occur, and might be more frequent than suspected. In view of their common use, their identification as allergenic culprits is important.

Application of D-optimal experimental design method to optimize the formulation of O/W cosmetic emulsions [PMID: 24127836 · 2014]
Djuris J, Vasiljevic D, Jokic S, Ibric S · Int J Cosmet Sci (2014)

This study investigates the application of D-optimal mixture experimental design in optimization of O/W cosmetic emulsions. Cetearyl glucoside was used as a natural, biodegradable non-ionic emulsifier in the relatively low concentration (1%), and the mixture of co-emulsifiers (stearic acid, cetyl alcohol, stearyl alcohol and glyceryl stearate) was used to stabilize the formulations. To determine the optimal composition of co-emulsifiers mixture, D-optimal mixture experimental design was used. Prepared emulsions were characterized with rheological measurements, centrifugation test, specific conductivity and pH value measurements. All prepared samples appeared as white and homogenous creams, except for one homogenous and viscous lotion co-stabilized by stearic acid alone. Centrifugation testing revealed some phase separation only in the case of sample co-stabilized using glyceryl stearate alone. The obtained pH values indicated that all samples expressed mild acid value acceptable for cosmetic preparations. Specific conductivity values are attributed to the multiple phases O/W emulsions with high percentages of fixed water. Results of the rheological measurements have shown that the investigated samples exhibited non-Newtonian thixotropic behaviour. To determine the influence of each of the co-emulsifiers on emulsions properties, the obtained results were evaluated by the means of statistical analysis (ANOVA test). On the basis of comparison of statistical parameters for each of the studied responses, mixture reduced quadratic model was selected over the linear model implying that interactions between co-emulsifiers play the significant role in overall influence of co-emulsifiers on emulsions properties. Glyceryl stearate was found to be the dominant co-emulsifier affecting emulsions properties. Interactions between the glyceryl stearate and other co-emulsifiers were also found to significantly influence emulsions properties. These findings are especially important as they can be used for development of the product that meets users' requirements, as represented in the study.

Development of a prospective isopropyl alcohol-loaded pharmaceutical base using simultaneous in vitro/in vivo characterization methods of skin performance [PMID: 23688275 · 2014]
Pantelic I, Lukic M, Markovic B, Lusiana, Hoffmann C, Müller-Goymann C, Milic J, Daniels R, Savic S · Drug Dev Ind Pharm (2014)

Approaching of pharmaceutical and cosmetic industries in some aspects inevitably influence formulation of topical pharmaceuticals, urging researchers to introduce novel excipients with proven benefits over traditional ones. In that context, alkyl polyglucosides (APG) emerge as prominent natural-origin emulsifiers with numerous favorable features (biodegradability, dermatological acceptability, desirable sensory properties). To evaluate APG-stabilized bases (alone and upon addition of isopropyl alcohol) and their impact on skin performance. A simultaneous in vitro/in vivo skin absorption study was conducted to evaluate whether the tape stripping technique could be recommended as an in vivo tool for skin penetration assessment during formulation optimization process. After a comprehensive physicochemical characterization, biopharmaceutical properties of APG-bases versus reference ones were assessed through a combined in vitro (release/permeation) and in vivo approach. Physicochemical characterization revealed substantial difference in structural ordering due to the formation of various mesomorphic phases. The enhancer-loaded APG base resulted in significantly higher drug levels at all depths into the stratum corneum, indicating that the selected enhancer along with specific colloidal structure has increased the extent of drug delivery. Results recommend the investigated emulsifier for stabilization of topical drug delivery systems, not only for their ability to sustain the addition of isopropyl alcohol which proved to be a valuable enhancer, but also satisfactory skin absorption and tolerability when compared to samples stabilized by conventional emulsifier. Tape stripping proved to be a useful and yet inexpensive tool for in vivo trials, able to discriminate subtle differences in dermal availability.

Interaction of epicutaneously applied lipids with stratum corneum depends on the presence of either emulsifiers or hydrogenated phosphatidylcholine [PMID: 20523109 · 2010]
Wohlrab J, Klapperstück T, Reinhardt HW, Albrecht M · Skin Pharmacol Physiol (2010)

The barrier function of the stratum corneum (SC) significantly determines the interaction of epicutaneously applied substances with the skin organ. Although the exact molecular processes are still unclear, it is undoubted that the intercellular lipid composition and order of the SC is significantly involved in this interaction. Topically substituted phases, especially those of lipophilic composition, seem to interact very intensely with lipid membranes; they can be integrated, form separate phases, or even permeate through the SC into the viable skin. The latter is not desired, especially in barrier-protective preparations with a lipophilic phase. The present paper investigates the penetration behavior of topically applied, DiI-labeled lipids into human ex vivo skin depending on the phase organization of different o/w emulsifiers compared to emulsifier-free preparations containing hydrogenated phosphatidylcholine by means of fluorescence indication. Results are presented for intact and defined damaged epidermal barrier. In addition, the washout effect based on skin samples treated by artificial watering after lipid incubation, and the influence of the phase transition temperature of the SC membrane were studied. The results show that in intact and damaged skin, the penetration depth of the lipids increases directly proportionally with the hydrophilic-lipophilic balance (HLB value), while the washout effect and the HLB value proved to be inversely related. An increase in penetration depth with higher HLB values was also apparent when the phase transition temperature of the physiological membranes was exceeded. Altogether, the results clearly demonstrate that the characteristics of the emulsifying phase of a preparation significantly determine the interaction of a substituted lipophilic phase with the SC. Especially bipolar lipids, like phosphatidylcholines, showed intradermal dispersion patterns which hint at an especially intense interaction with physiological membranes.

Natural surfactant-based topical vehicles for two model drugs: Influence of different lipophilic excipients on in vitro/in vivo skin performance [PMID: 19616085 · 2009]
Savić S, Weber C, Savić MM, Müller-Goymann C · Int J Pharm (2009)

This study focuses on the properties of topical vehicles based on alkylpolyglucoside natural surfactant-mixed emulsifier, cetearyl glucoside and cetearyl alcohol, in order to propose their use as "ready to use" pharmaceutical bases for a number of model drugs. We were interested to investigate how the alternative use of three lipophilic excipients (Ph. Eur. 6.0), differing in their polarity indexes (medium chain triglycerides (MG), decyl oleate (DO), and isopropyl myristate (IPM), respectively), affects the colloidal structure of the alkylpolyglucoside-based vehicles and in vitro permeation profiles of two model drugs: diclofenac sodium (DC) and caffeine (CF), both sparingly soluble in water. Finally, we aimed to evaluate the safety profile of such vehicles in vitro (acute skin irritation test using a cytotoxicity assay), comparing it with in vivo data obtained by the methods of skin bioengineering. The results have shown that the emulsion vehicles consisted of a complex colloidal structure of lamellar liquid crystalline and lamellar gel crystalline type. Varying of lipophilic excipient influenced noteworthy variations in the colloidal structure demonstrated as different rheological profiles accompanied to the certain degree by different water distribution modes, but notably provoked by drug nature (an amphiphilic electrolyte drug vs. nonelectrolyte). In vitro permeation data obtained using ASC membranes in an infinite dose-type of experiment stressed the importance of the vehicle/solute interactions in case of small variation in formulation composition, asserting the drug properties in the first hours of permeation and rheological profile of the vehicles in the later phase of experiment as decisive factors. In vitro skin irritation test demonstrated a mild nature of the emulsifying wax and the absence of negative effects of used oil phases on cell viability in formulation concentrations correspondent to the therapeutic need. This result alongside with data obtained from in vivo study, could additionally promote investigated topical vehicles as prospective "ready to use" pharmaceutical bases.

Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: The influence of two polyols on the colloidal structure and in vitro/in vivo skin performance [PMID: 18937361 · 2009]
Savic S, Weber C, Tamburic S, Savic M, Müller-Goymann C · J Pharm Sci (2009)

There is a growing need for in-depth research into new skin- and environment-friendly surfactants, such as alkylpolyglucosides. The aim of this study was to assess whether, to which extent and by what mechanism the two commonly used hydrophilic excipients, propylene glycol (PG) and glycerol (GL), affect the colloidal structure of emulsions formed by a natural mixed emulsifier, cetearyl glucoside and cetearyl alcohol. Furthermore, the study was concerned with the effect of these changes on in vitro permeation profiles of two model drugs (diclofenac sodium and caffeine) and in vivo skin performance of the test samples. The results have shown that the emulsion vehicles consisted of a complex colloidal structure of lamellar liquid crystalline and lamellar gel crystalline type. PG addition produced a stronger hydrophilic lamellar gel phase than GL, which was independent on the model drug used. PG-containing vehicles have revealed a considerable amount of interlamellar PG/water mixture, with incorporated drug. In vitro permeation data obtained using artificial skin constructs (ASC) confirmed the relationship between rheological profiles of vehicles and the extent of skin delivery. Higher permeation profiles of both drugs from PG-containing formulations coincided with a higher increase in transepidermal water loss observed in in vivo study on human volunteers, which confirms the penetration/permeation enhancer effect of PG. It also indicates the existence of the vehicle/ASC interactions analogous to those between the vehicle and the skin, thus affirming the use of ASC as a reliable tool for permeation studies. Contrary to the effect of PG, the results obtained with GL suggest that it may have a permeation-retarding rather than a permeation-enhancing effect in topical vehicles of this type.

In vitro skin permeation of sunscreen agents from O/W emulsions [PMID: 18377631 · 2008]
Montenegro L, Carbone C, Paolino D, Drago R, Stancampiano AH, Puglisi G · Int J Cosmet Sci (2008)

The effects of different emulsifiers on the in vitro permeation through human skin of two sunscreen agents [octylmethoxycinnamate (OMC) and butylmethoxydibenzoylmethane (BMBM)] were investigated from O/W emulsions. The test formulations were prepared using the same oil and aqueous phase ingredients and the following emulsifier and coemulsifier systems: Emulgade SE((R)) (ceteareth-12 and ceteareth-20 and cetearyl alcohol and cetyl palmitate) and glycerylmonostearate (emulsion 1); Brij 72((R)) (steareth-2), Brij 721((R)) (steareth-21) and cetearyl alcohol (emulsion 2); Phytocream((R)) (potassium palmitoyl-hydrolysed wheat protein and glyceryl stearate and cetearyl alcohol) and glycerylmonostearate (emulsion 3); Montanov 68((R)) (cetearyl glucoside and cetearyl alcohol) (emulsion 4); Xalifin-15((R)) (C(15-20) acid PEG-8 ester) and cetearyl alcohol (emulsion 5). The cumulative amount of OMC that permeated in vitro through human skin after 22 h from the formulations being tested decreased in the order 3 > 1 congruent with 4 > 5 > 2 and was about nine-fold higher from emulsion 3 compared with that from emulsion 2. As regards BMBM, no significant difference was observed as regards its skin permeation from emulsions 1, 3, 4 and 5, whereas formulation 2 allowed significantly lower amounts of BMBM to permeate the skin. In vitro release experiments of OMC and BMBM from emulsions 1-6 through cellulose acetate membranes showed that only emulsions 4 and 5 provided pseudo-first-order release rates only for OMC. The results of this study suggest that the type of emulsifying systems used to prepare an O/W emulsion may strongly affect sunscreen skin permeation from these formulations. Therefore, the vehicle effects should be carefully considered in the formulation of sunscreen products.

よくある質問 (FAQ)

Q1. CETEARYL GLUCOSIDE の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'CETEARYL GLUCOSIDE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'CETEARYL GLUCOSIDE'、中国NMPA IECIC標準中国語名は '鲸蜡硬脂基葡糖苷' です。
Q2. CETEARYL GLUCOSIDE のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における CETEARYL GLUCOSIDE の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (emulsion_cream) において通常 1〜5%(中央値 2.5%)で配合され、適正pH範囲は 3〜10 です。
Q4. CETEARYL GLUCOSIDE の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは CETEARYL ALCOHOL, CAPRYLIC/CAPRIC TRIGLYCERIDE, SQUALANE, XANTHAN GUM、配合上の注意点は Requires emulsification temperature ≥ 75°C to fully melt cetearyl alcohol co-crystals です。